Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic/Locally Advanced Breast Cancer: PERTAIN Final Analysis
CONCLUSIONS: The PFS benefit of pertuzumab was maintained and OS was similar between arms at final analysis. Adding pertuzumab may enhance activity in patients who do not require first-line chemotherapy for M/LABC. No new safety concerns were reported. These data provide additional evidence of the role of first-line pertuzumab and trastuzumab in HER2-positive M/LABC.PMID:36716289 | DOI:10.1158/1078-0432.CCR-22-1092 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 30, 2023 Category: Cancer & Oncology Authors: Grazia Arpino Juan de la Haba-Rodr íguez Jean-Marc Ferrero Sabino De Placido C Kent Osborne Dirk Klingbiel Valentine Revelant Christine Wohlfarth Raf Poppe Mothaffar F Rimawi Source Type: research
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic/Locally Advanced Breast Cancer: PERTAIN Final Analysis
CONCLUSIONS: The PFS benefit of pertuzumab was maintained and OS was similar between arms at final analysis. Adding pertuzumab may enhance activity in patients who do not require first-line chemotherapy for M/LABC. No new safety concerns were reported. These data provide additional evidence of the role of first-line pertuzumab and trastuzumab in HER2-positive M/LABC.PMID:36716289 | DOI:10.1158/1078-0432.CCR-22-1092 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 30, 2023 Category: Cancer & Oncology Authors: Grazia Arpino Juan de la Haba-Rodr íguez Jean-Marc Ferrero Sabino De Placido C Kent Osborne Dirk Klingbiel Valentine Revelant Christine Wohlfarth Raf Poppe Mothaffar F Rimawi Source Type: research
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic/Locally Advanced Breast Cancer: PERTAIN Final Analysis
CONCLUSIONS: The PFS benefit of pertuzumab was maintained and OS was similar between arms at final analysis. Adding pertuzumab may enhance activity in patients who do not require first-line chemotherapy for M/LABC. No new safety concerns were reported. These data provide additional evidence of the role of first-line pertuzumab and trastuzumab in HER2-positive M/LABC.PMID:36716289 | DOI:10.1158/1078-0432.CCR-22-1092 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 30, 2023 Category: Cancer & Oncology Authors: Grazia Arpino Juan de la Haba-Rodr íguez Jean-Marc Ferrero Sabino De Placido C Kent Osborne Dirk Klingbiel Valentine Revelant Christine Wohlfarth Raf Poppe Mothaffar F Rimawi Source Type: research
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer
CONCLUSIONS: Rarely does NAI result in pCR for patients with stage 2 or 3 ER+ BC. However, a significant proportion will have downstaged to allow for BCS. Local-regional recurrence after surgery is uncommon (1.5% at 5 years), supporting the use of BCS after NAI.PMID:36653664 | DOI:10.1245/s10434-022-12972-5 (Source: Ann Oncol)
Source: Ann Oncol - January 18, 2023 Category: Cancer & Oncology Authors: Kelly K Hunt Vera J Suman Hannah F Wingate A Marilyn Leitch Gary Unzeitig Judy C Boughey Funda Meric-Bernstam Matthew J Ellis John Olson Source Type: research
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer
CONCLUSIONS: Rarely does NAI result in pCR for patients with stage 2 or 3 ER+ BC. However, a significant proportion will have downstaged to allow for BCS. Local-regional recurrence after surgery is uncommon (1.5% at 5 years), supporting the use of BCS after NAI.PMID:36653664 | DOI:10.1245/s10434-022-12972-5 (Source: Ann Oncol)
Source: Ann Oncol - January 18, 2023 Category: Cancer & Oncology Authors: Kelly K Hunt Vera J Suman Hannah F Wingate A Marilyn Leitch Gary Unzeitig Judy C Boughey Funda Meric-Bernstam Matthew J Ellis John Olson Source Type: research
Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone vs. Endocrine Therapy Alone or Combined Treatment for Low-Risk ER-positive Early-Stage Breast Cancer in Women Age 65 and Older
CONCLUSIONS: U-WBI alone appears the more cost-effective de-escalation strategy for these patients, compared to AI alone. Combining U-WBI and AI appears more costly but may be preferred by some patients.PMID:36586492 | DOI:10.1016/j.ijrobp.2022.12.028 (Source: Health Physics)
Source: Health Physics - December 31, 2022 Category: Physics Authors: Matthew C Ward Abram Recht Frank Vicini Zahraa Al-Hilli Wafa Asha Manjeet Chadha Abel Abraham Nikhil Thaker Atif J Khan Martin Keisch Chirag Shah Source Type: research
iPSCs-derived mesenchymal stromal cells mitigate anxiety and neuroinflammation in aging female mice
In conclusion, iPSC-derived MSCs may provide a novel option to manage perimenopause-related hormonal dysregulation and neurological disorders during the female aging process.PMID:36565990 | DOI:10.1016/j.biocel.2022.106347 (Source: The International Journal of Biochemistry and Cell Biology)
Source: The International Journal of Biochemistry and Cell Biology - December 24, 2022 Category: Biochemistry Authors: Xiaoyue Wei Ruijie Li Xiangyu Li Boyan Wang Jianyang Huang Hanyiqi Mu Qinmu Zhang Ziyuan Zhang Yifei Ru Xinxiang Wu Yuan Qiu Yanchen Ye Yuanyuan Feng Shiyu Wang Hui Chen Chenju Yi Jiancheng Wang Source Type: research
iPSCs-derived mesenchymal stromal cells mitigate anxiety and neuroinflammation in aging female mice
In conclusion, iPSC-derived MSCs may provide a novel option to manage perimenopause-related hormonal dysregulation and neurological disorders during the female aging process.PMID:36565990 | DOI:10.1016/j.biocel.2022.106347 (Source: The International Journal of Biochemistry and Cell Biology)
Source: The International Journal of Biochemistry and Cell Biology - December 24, 2022 Category: Biochemistry Authors: Xiaoyue Wei Ruijie Li Xiangyu Li Boyan Wang Jianyang Huang Hanyiqi Mu Qinmu Zhang Ziyuan Zhang Yifei Ru Xinxiang Wu Yuan Qiu Yanchen Ye Yuanyuan Feng Shiyu Wang Hui Chen Chenju Yi Jiancheng Wang Source Type: research
Effect of Aromatase Inhibitors on Serum Calprotectin Levels in an Animal Experimental Model: Trial
CONCLUSION: The potential of hepatotoxicity can be examined by assessing the elevation of inflammation markers such as Calprotectin, which is an indicator that should be strictly taken into consideration when administering aromatase inhibitors as treatment.PMID:36340459 | PMC:PMC9628141 | DOI:10.21873/cdp.10167 (Source: Cancer Control)
Source: Cancer Control - November 7, 2022 Category: Cancer & Oncology Authors: Ioannis Boutas Adamantia Kontogeorgi Nektarios Koufopoulos Constantine Dimitrakakis Dionysios Dimas Sophia N Kalantaridou Laskarina-Maria Korou Despoina Perrea Source Type: research
Steroidal and nonsteroidal aromatase inhibitors induced dermatitis- a case report of cross-reactivity
We describe a unique case of reaction to both classes of AI. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2022 Category: Allergy & Immunology Authors: M. Ebrahim, Z. Treyster Tags: M007 Source Type: research
39. Associations between somatically altered genes and recurrence outcomes in estrogen receptor positive breast cancer
The relationships between somatic mutations, copy number alterations (CNA) and outcomes in estrogen receptor positive (ER+) breast cancer is understudied. We have earlier published associations between rare and low frequency mutations and clinical outcomes in ER+ disease (PMID:30181556).As an extension of the study, FFPE blocks were obtained from 889 additional patients from the TransATAC study, an Anastrozole (A) or Tamoxifen (T) alone or combined randomized trial with 10-year follow-up. Tumor samples were reviewed, DNA isolated, and targeted sequencing performed for 83 genes. (Source: Cancer Genetics and Cytogenetics)
Source: Cancer Genetics and Cytogenetics - November 1, 2022 Category: Genetics & Stem Cells Authors: Meenakshi Anurag, Kim Chu, Brian Li, Ivana Sestak, Eugene Schuster, Zachary Skidmore, Nicholas Spies, Jason Kunisaki, Catrina Fronick, Robert Fulton, Malachi Griffith, Richard Buss, Jack Cuzick, Obi L. Griffith, Mitchell Dowsett, Matthew Ellis Source Type: research
Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors
CONCLUSION: The non-inferiority of NHT in relation to NCT will provide further evidence that replacing NCT with NHT is safe and effective in eligible patients, which is particularly relevant for populations with limited access to health services and for institutions with few available resources.PMID:36262803 | PMC:PMC9574413 | DOI:10.1016/j.conctc.2022.101013 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 20, 2022 Category: Cancer & Oncology Authors: Maria Carolina Gouveia Candice Amorim de Ara újo Lima Santos Ariani Impieri Souza Source Type: research
Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors
CONCLUSION: The non-inferiority of NHT in relation to NCT will provide further evidence that replacing NCT with NHT is safe and effective in eligible patients, which is particularly relevant for populations with limited access to health services and for institutions with few available resources.PMID:36262803 | PMC:PMC9574413 | DOI:10.1016/j.conctc.2022.101013 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - October 20, 2022 Category: Cancer & Oncology Authors: Maria Carolina Gouveia Candice Amorim de Ara újo Lima Santos Ariani Impieri Souza Source Type: research
Molecules, Vol. 27, Pages 6742: Theoretical Study on the Aggregation and Adsorption Behaviors of Anticancer Drug Molecules on Graphene/Graphene Oxide Surface
Yanyan Jiang
Graphene and its derivatives are frequently used in cancer therapy, and there has been widespread interest in improving the therapeutic efficiency of targeted drugs. In this paper, the geometrical structure and electronic effects of anastrozole(Anas), camptothecin(CPT), gefitinib (Gefi), and resveratrol (Res) on graphene and graphene oxide(GO) were investigated by density functional theory (DFT) calculations and molecular dynamics (MD) simulation. Meanwhile, we explored and compared the adsorption process between graphene/GO and four drug molecules, as well as the adsorption sites between carriers and pay...
Source: Molecules - October 10, 2022 Category: Chemistry Authors: Pengyu Gong Yi Zhou Hui Li Jie Zhang Yuying Wu Peiru Zheng Yanyan Jiang Tags: Article Source Type: research
Escitalopram co-prescription in anastrozole-treated breast cancer patients
CONCLUSION: Escitalopram co-prescription resulted in significant increase in plasma anastrozole levels without affecting the serum estradiol levels. Our findings emphasize the need for close monitoring in case of concomitant use of anastrozole and escitalopram, especially in obese patients and the potential role of therapeutic drug monitoring.PMID:36199859 | PMC:PMC9464843 | DOI:10.14744/nci.2022.48264 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - October 6, 2022 Category: Cancer & Oncology Authors: Hazan Ozyurt Sevgi Ozden Cengiz Gemici Esra Kucukibrahimoglu Hatice Odabas Neset Nesetoglu Durisehvar Unal Pinar Uler Gokhan Yaprak Huseyin Tepetam Mahmut Gumus Mehmet Zafer Goren Source Type: research
